CA-XPRIZE
3.10.2020 03:10:11 CEST | Business Wire | Press release
XPRIZE today announced that the million dollar Next-Gen Mask Challenge received record-breaking team entry numbers in their newest initiative that called upon young innovators from around the world ages 15 to 24 to reimagine protective face masks. By limiting participation to youth participants, XPRIZE aimed to galvanize the next generation of innovators, and the overwhelming response demonstrated the eagerness of Gen-Z creators to make an impact on the world.
Within 60 days, the XPRIZE Next-Gen Mask Challenge received 992 interested participants, making it the largest, most prolific call-to-action in XPRIZE Foundation history. Potential teams originated from 76 countries, proof of the global desire to overcome many of the common barriers associated with traditional protective masks.
“We understand that masks can be ill-fitting, uncomfortable, unfashionable, and that the most effective masks are often unavailable or expensive for everyday people. We need an alternative, that’s why XPRIZE is turning to the world’s young innovators to help reinvent the face mask and create an accessible alternative that will help protect against the spread of COVID-19,” said Peter H. Diamandis, XPRIZE founder and executive chairman. “We’re going to take the top 25 designs and find out if they’re manufacturable. Once we determine their manufacturability, we’re going to take the top 10 of those and go out to influencers to gauge acceptance.”
XPRIZE, a nonprofit organization that uses global competitions to crowdsource solutions to some of the world’s biggest challenges, recognized that currently one-third of the US population doesn’t regularly wear a mask, despite evidence showing that when used properly they can significantly reduce transmission of viruses. The $1M XPRIZE Next-Gen Mask Challenge contest, sponsored by Marc Benioff and Jim Cramer, will award the grand prize to young innovators whose mask design best combines ingenuity, effectiveness, X-factor of style, and ability to overcome common barriers to use as measured by a pre-Challenge poll taken by over 3,000 participants.
“There is a gigantic amount of evidence that masks can stop the spread,” said Jim Cramer, the host of Mad Money on CNBC. “I’m so proud to sponsor the XPRIZE Next-Gen Mask Challenge with Marc Benioff, it's amazing how resourceful people are when you ask them to design a mask that those who object to most masks might even wear.”
“If everyone in the United States wore a mask for 3 weeks — just 3 weeks — we would not have anymore coronavirus, because there would be no more spread, but people do not want to wear masks,” said sponsor Marc Benioff.
XPRIZE’s Next-Gen Mask Challenge will culminate in a final judging event, with in-lab testing this October supported by partners 3M and Honeywell and winners will be announced later this year. Additional details and the list of teams moving forward can be found here.
ABOUT XPRIZE
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE, the $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling, XPRIZE NextGen Mask Challenge and $5 Million XPRIZE Rapid COVID Testing. For more information, visit xprize.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201002005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
